Zhongsheng Pharmaceutical: Stock volatility triggers disclosure
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) has announced that its stock experienced abnormal fluctuations, triggering a disclosure under Shenzhen Stock Exchange rules. The company confirmed that there are no undisclosed material events or pending significant strategic initiatives. Key projects, including the RAY1225 injection, a GLP-1 agonist for diabetes and obesity treatment, are progressing with clinical trials underway, though outcomes remain uncertain. Additionally, the company is reallocating unused funds from "Anti-tumor drug R&D projects" and "Digital Platform upgrade projects," totaling CNY 10,307,540 to a new drug development project by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. The company has urged investors to exercise caution and seek professional advice.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Guangdong Zhongsheng Pharmaceutical publishes news
Free account required • Unsubscribe anytime